The BRACE Award aims to provide vital support to early-stage biotechs, enabling them to accelerate their innovative therapeutics, diagnostics and cancer prevention products into the clinic, with the ultimate goal of improving outcomes for patients affected by cancer globally.

The winning company will receive up to US$600,000 in investment funding from AFCR and co-investors, subject to due diligence and negotiation, which will serve as early seed money for proof of concept and proof of value on the path to clinical trials and, eventually, to new effective cancer technologies that could save patients’ lives.